Cara B Ebbeling1,2, Amy Knapp3, Ann Johnson4, Julia M W Wong1,2, Kimberly F Greco5, Clement Ma2,6, Samia Mora2,7, David S Ludwig1,2. 1. New Balance Foundation Obesity Prevention Center, Boston Children's Hospital, Boston, MA, USA. 2. Harvard Medical School, Boston, MA, USA. 3. Department of Biology, Framingham State University, Framingham, MA, USA. 4. Department of Food and Nutrition, Framingham State University, Framingham, MA, USA. 5. Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA, USA. 6. Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA. 7. Center for Lipid Metabolomics, Divisions of Preventive and Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Carbohydrate restriction shows promise for diabetes, but concerns regarding high saturated fat content of low-carbohydrate diets limit widespread adoption. OBJECTIVES: This preplanned ancillary study aimed to determine how diets varying widely in carbohydrate and saturated fat affect cardiovascular disease (CVD) risk factors during weight-loss maintenance. METHODS: After 10-14% weight loss on a run-in diet, 164 participants (70% female; BMI = 32.4 ± 4.8 kg/m2) were randomly assigned to 3 weight-loss maintenance diets for 20 wk. The prepared diets contained 20% protein and differed 3-fold in carbohydrate (Carb) and saturated fat as a proportion of energy (Low-Carb: 20% carbohydrate, 21% saturated fat; Moderate-Carb: 40%, 14%; High-Carb: 60%, 7%). Fasting plasma samples were collected prerandomization and at 20 wk. Lipoprotein insulin resistance (LPIR) score was calculated from triglyceride-rich, high-density, and low-density lipoprotein particle (TRL-P, HDL-P, LDL-P) sizes and subfraction concentrations (large/very large TRL-P, large HDL-P, small LDL-P). Other outcomes included lipoprotein(a), triglycerides, HDL cholesterol, LDL cholesterol, adiponectin, and inflammatory markers. Repeated measures ANOVA was used for intention-to-treat analysis. RESULTS: Retention was 90%. Mean change in LPIR (scale 0-100) differed by diet in a dose-dependent fashion: Low-Carb (-5.3; 95% CI: -9.2, -1.5), Moderate-Carb (-0.02; 95% CI: -4.1, 4.1), High-Carb (3.6; 95% CI: -0.6, 7.7), P = 0.009. Low-Carb also favorably affected lipoprotein(a) [-14.7% (95% CI: -19.5, -9.5), -2.1 (95% CI: -8.2, 4.3), and 0.2 (95% CI: -6.0, 6.8), respectively; P = 0.0005], triglycerides, HDL cholesterol, large/very large TRL-P, large HDL-P, and adiponectin. LDL cholesterol, LDL-P, and inflammatory markers did not differ by diet. CONCLUSIONS: A low-carbohydrate diet, high in saturated fat, improved insulin-resistant dyslipoproteinemia and lipoprotein(a), without adverse effect on LDL cholesterol. Carbohydrate restriction might lower CVD risk independently of body weight, a possibility that warrants study in major multicentered trials powered on hard outcomes. The registry is available through ClinicialTrials.gov: https://clinicaltrials.gov/ct2/show/NCT02068885.
BACKGROUND: Carbohydrate restriction shows promise for diabetes, but concerns regarding high saturated fat content of low-carbohydrate diets limit widespread adoption. OBJECTIVES: This preplanned ancillary study aimed to determine how diets varying widely in carbohydrate and saturated fat affect cardiovascular disease (CVD) risk factors during weight-loss maintenance. METHODS: After 10-14% weight loss on a run-in diet, 164 participants (70% female; BMI = 32.4 ± 4.8 kg/m2) were randomly assigned to 3 weight-loss maintenance diets for 20 wk. The prepared diets contained 20% protein and differed 3-fold in carbohydrate (Carb) and saturated fat as a proportion of energy (Low-Carb: 20% carbohydrate, 21% saturated fat; Moderate-Carb: 40%, 14%; High-Carb: 60%, 7%). Fasting plasma samples were collected prerandomization and at 20 wk. Lipoprotein insulin resistance (LPIR) score was calculated from triglyceride-rich, high-density, and low-density lipoprotein particle (TRL-P, HDL-P, LDL-P) sizes and subfraction concentrations (large/very large TRL-P, large HDL-P, small LDL-P). Other outcomes included lipoprotein(a), triglycerides, HDL cholesterol, LDL cholesterol, adiponectin, and inflammatory markers. Repeated measures ANOVA was used for intention-to-treat analysis. RESULTS: Retention was 90%. Mean change in LPIR (scale 0-100) differed by diet in a dose-dependent fashion: Low-Carb (-5.3; 95% CI: -9.2, -1.5), Moderate-Carb (-0.02; 95% CI: -4.1, 4.1), High-Carb (3.6; 95% CI: -0.6, 7.7), P = 0.009. Low-Carb also favorably affected lipoprotein(a) [-14.7% (95% CI: -19.5, -9.5), -2.1 (95% CI: -8.2, 4.3), and 0.2 (95% CI: -6.0, 6.8), respectively; P = 0.0005], triglycerides, HDL cholesterol, large/very large TRL-P, large HDL-P, and adiponectin. LDL cholesterol, LDL-P, and inflammatory markers did not differ by diet. CONCLUSIONS: A low-carbohydrate diet, high in saturated fat, improved insulin-resistant dyslipoproteinemia and lipoprotein(a), without adverse effect on LDL cholesterol. Carbohydrate restriction might lower CVD risk independently of body weight, a possibility that warrants study in major multicentered trials powered on hard outcomes. The registry is available through ClinicialTrials.gov: https://clinicaltrials.gov/ct2/show/NCT02068885.
Authors: Jacquelaine Bartlett; Irene M Predazzi; Scott M Williams; William S Bush; Yeunjung Kim; Stephen Havas; Peter P Toth; Sergio Fazio; Michael Miller Journal: Circ Cardiovasc Qual Outcomes Date: 2016-05-10
Authors: Cara B Ebbeling; Gloria L Klein; Patricia K Luoto; Julia M W Wong; Lisa Bielak; Ralph G Eddy; Sarah K Steltz; Courtenay Devlin; Megan Sandman; Bridget Hron; Kim Shimy; Steven B Heymsfield; Robert R Wolfe; William W Wong; Henry A Feldman; David S Ludwig Journal: Contemp Clin Trials Date: 2017-12-09 Impact factor: 2.226
Authors: Sagar B Dugani; Akintunde O Akinkuolie; Nina Paynter; Robert J Glynn; Paul M Ridker; Samia Mora Journal: JAMA Cardiol Date: 2016-05-01 Impact factor: 14.676
Authors: Don P Wilson; Terry A Jacobson; Peter H Jones; Marlys L Koschinsky; Catherine J McNeal; Børge G Nordestgaard; Carl E Orringer Journal: J Clin Lipidol Date: 2019-05-17 Impact factor: 5.365
Authors: Harold E Bays; Anandita Kulkarni; Charles German; Priyanka Satish; Adedapo Iluyomade; Ramzi Dudum; Aarti Thakkar; Mahmoud Al Rifai; Anurag Mehta; Aneesha Thobani; Yousif Al-Saiegh; Adam J Nelson; Samip Sheth; Peter P Toth Journal: Am J Prev Cardiol Date: 2022-04-06
Authors: Inês V da Silva; Sean Gullette; Cristina Florindo; Neil K Huang; Thomas Neuberger; A Catharine Ross; Graça Soveral; Rita Castro Journal: Biomedicines Date: 2022-05-18
Authors: Lukas Cipryan; Martina Litschmannova; Philip B Maffetone; Daniel J Plews; Tomas Dostal; Peter Hofmann; Paul B Laursen Journal: Front Nutr Date: 2022-05-23
Authors: Nicholas G Norwitz; Adrian Soto-Mota; Bob Kaplan; David S Ludwig; Matthew Budoff; Anatol Kontush; David Feldman Journal: Metabolites Date: 2022-05-20